Silver Sulfadiazine (Silver Sulfadiazine) Patent Expiration, LOE Window & CMS Spending

Silver Sulfadiazine (Silver Sulfadiazine) by Ascend Laborato: Multi-Source Generic Molecule, 2 AB generics, $6.8M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAscend Laborato
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$6.8M
2024 Medicare Part D Spend$4.8M
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 56.4% 2-yr change)